Lakhasly

Benazepril's ACE inhibitory action hinges on a proline-like core mimicking angiotensin I's transition state, enabling competitive inhibition. A carboxylate group crucial for activity binds the active site's zinc ion; modifications reduce activity until hydrolysis restores the diacid form. An ethyl ester improves oral bioavailability via increased lipophilicity, hydrolyzing in vivo to the active benazeprilat. A phenyl group boosts ACE binding affinity through hydrophobic interactions, while the side chain and benzazepine ring influence pharmacokinetics and binding, respectively.

Proline-like Core:
The proline-like structure is essential for binding to the active site of ACE.

This core mimics the transition state of the peptide substrate (angiotensin I), allowing competitive inhibition.

Zinc-Binding Group:
The carboxylate group (–COOH) interacts with the zinc ion in the active site of ACE, which is critical for inhibitory activity.

Modifications to this group (e.g., esterification) reduce activity until hydrolyzed to the active diacid form.

Ester Prodrug:
The ethyl ester group (–COOCH2CH3) improves oral bioavailability by increasing lipophilicity.

Hydrolysis of the ester group in vivo produces the active diacid metabolite, benazeprilat.
Phenyl Group:
The phenyl group enhances binding affinity to ACE by interacting with hydrophobic regions of the enzyme.

Side Chain:
The side chain of benazepril contributes to its pharmacokinetic properties, such as absorption and distribution.

The benzazepine ring (a fused bicyclic structure) provides rigidity and enhances binding affinity.